Factors and Outcomes Associated With Postpartum Cabergoline Use

NCT03965572 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-09-28

No results posted yet for this study

Summary

Cabergoline is frequently being requested by many postpartum women with a live newborn to suppress lactation. The aim of the study is to investigate which women desire such an intervention, and what side effects they are experiencing.

Conditions

Sponsors & Collaborators

  • Laniado Hospital

    lead OTHER

Principal Investigators

  • Sarit Kalfon, MD · Laniado Hospital

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-07
Primary Completion
2022-12-31
Completion
2023-05-12

Countries

  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03965572 on ClinicalTrials.gov